Search Result

Results for "

CCK 8

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cholecystokinin Receptor (8) Akt (2) Apoptosis (2) PI3K (2) Ser/Thr Protease (1)
By Research Areas:	Cancer (2) Endocrinology (4) Infection (2) Metabolic Disease (5) Neurological Disease (3)

Inhibitors & Agonists

Peptides

MCE Kits

Targets Recommended: Cholecystokinin Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0093

Sincalide 3 Publications Verification Cholecystokinin octapeptide; CCK-8; SQ19844	Cholecystokinin Receptor Apoptosis PI3K Akt	Infection Cancer
Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK .

HY-P0093A

Sincalide ammonium 3 Publications Verification Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium	Cholecystokinin Receptor Apoptosis PI3K Akt	Infection Cancer
Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK .

HY-128878

Dexloxiglumide	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist . Dexloxiglumide, the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8) .

HY-107759

Butabindide oxalate UCL-1397 oxalate	Others	Neurological Disease
Butabindide (UCL-1397) oxalate is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with K_i values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide oxalate inhibits TPP II to protect CCK-8 against inactivation .

HY-P1710

ARL 15849XX	Cholecystokinin Receptor	Endocrinology
ARL 15849XX is a cholecystokinin-8 (CCK-8) analog .

HY-118194

A-65186	Others	Others
A-65186 is a CCK-A receptor antagonist with the activity of inhibiting CCK8-induced amylase secretion. A-65186 has high binding affinity for pancreatic CCK-A receptors, is more than 500 times more selective for CCK-A receptors than for CCK-B receptors, and can inhibit CCK8-induced amylase secretion.

HY-116576

LY219057	Cholecystokinin Receptor	Metabolic Disease
LY219057 is a potent antagonist of cholecystokinin octapeptide (CCK-8), with the ID₅₀ of 287.5 nM .

HY-150070

Butabindide UCL-1397	Ser/Thr Protease	Neurological Disease
Butabindide (UCL-1397) is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with K_i values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide inhibits TPP II to protect CCK-8 against inactivation .

HY-100481

RP 72540 RPR101048	Cholecystokinin Receptor	Neurological Disease
RP 72540 is a selective *CCK-B* receptor antagonist, with IC₅₀ values of 2.4, 1.2, and 3.8 nM for *CCK-B* receptors in the guinea pig cerebral cortex, rat cerebral cortex, and mouse brain, respectively. RP 72540 effectively inhibits *CCK-8*-induced neuronal firing and dose-dependently inhibits gastric acid secretion, making it potentially valuable in studies of acid secretion. RP 72540 is an important tool for investigating the physiological functions of CCK B receptors .

HY-19261

T-0632	Others	Metabolic Disease
T-0632 is a CCK A receptor antagonist that exhibits significant pharmacological properties in in vitro studies. T-0632 competitively inhibits the binding of [125I]CCK-8 to rat pancreatic CCK A receptors with a K_i value of 0.24 nM, which is significantly lower than the K_i value for guinea pig CCK B receptors. T-0632 has higher selectivity in inhibiting CCK-8-stimulated pancreatic enzyme release, with an IC_50 value of 5.0 nM, which is more advantageous than L-364,718 and loxiglumide. In rabbit gallbladder smooth muscle, the antagonistic effects of T-0632 and loxiglumide are reversible, while L-364,718 shows a persistent inhibitory effect. These results indicate that T-0632 is a highly potent, reversible and more selective CCK A receptor antagonist.

HY-118665

L-736380	Cholecystokinin Receptor	Metabolic Disease
L-736380 is a high affinity CCK-B (cholecystokinin B receptor) receptor antagonist, with IC₅₀ values of 0.054 nM and 400 nM for CCK-B and CCK-A, respectively. L-736380 dose-dependently inhibits gastric acid secretion in anesthetized rats (ID₅₀, 0.064 mg/kg) and ex vivo binding of [125I]CCK-8S in BKTO mice brain membranes (ED₅₀, 1.7 mg/kg) .

HY-14850

Sograzepide Netazepide; YF 476; YM-220	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent , highly selective and orally active *Gastrin/CCK-B* antagonist with an IC₅₀ value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC₅₀ of 502 nM . Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with K_i values of 0.068, 0.62 and 0.19 nM, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P0093

Sincalide 3 Publications Verification Cholecystokinin octapeptide; CCK-8; SQ19844	Cholecystokinin Receptor Apoptosis PI3K Akt	Infection Cancer
Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK .

HY-P0093A

Sincalide ammonium 3 Publications Verification Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium	Cholecystokinin Receptor Apoptosis PI3K Akt	Infection Cancer
Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK .

HY-P1710

ARL 15849XX	Cholecystokinin Receptor	Endocrinology
ARL 15849XX is a cholecystokinin-8 (CCK-8) analog .

HY-P2055

A-57696	Peptides	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

HY-P5519

[Thr28, Nle31]-Cholecystokinin (25-33), sulfated	Peptides	Others
[Thr28, Nle31]-Cholecystokinin (25-33) is a biological active peptide. (Cholecystokinin (CCK) acts both as a hormone and a neurotransmitter and is found in the GI system and the central nervous system. It is a satiety peptide that inhibits food intake.This Cholecystokinin (CCK) analog retains all the bioactivities of CCK8, but was found to be remarkably more stable in acidic media and unaffected by air oxidation due to Met replacements (Thr 28 and Nle31 were substituted for Methionine). The predominant conformation contains a gamma-turn centered on Thr4, separated by Gly5 from a helical segment that comprises the C-terminal residues.)

HY-P1133

Galanin (2-29) (rat) Rat galanin(2-29)	Peptides	Others
Galanin (2-29) (rat) inhibits rat pancreatic protein and CCK-8-stimulated amylase secretion. Galanin (2-29) (rat) is an GAL2R agonist (K_i: 3.5 nM) .

Cat. No.	Product Name

HY-K0301

Cell Counting Kit-8 2665+ Cited Publications
Cell Counting Kit-8 (CCK-8) allows sensitive colorimetric assays for the determination of cell viability in cell proliferation and cytotoxicity assays.

HY-K1090

Cytotoxicity LDH Assay Kit 5+ Cited Publications
MCE Cytotoxicity LDH Assay Kit can detect LDH activity in the culture supernatant, which is indicative of cytotoxicity. Meanwhile viable cell number can be detected by CCK8 Kit (HY-K0301).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.